Parkinson’s Disease Therapeutics Market Size Surpass USD 13.34 Bn by 2034

According to Precedence Research, the global parkinson’s disease therapeutics market size is expected to achieve USD 13.34 billion by 2034, increasing from USD 6.59 billion in 2024. In terms of CAGR, the market is poised to grow at a compound annual growth rate (CAGR) of 7.39% from 2025 to 2034.

Parkinson’s Disease Therapeutics Market Overview

Parkinson’s disease (PD) therapeutics are treatments used to treat and manage symptoms of PD. The key therapy for PD is dopamine replacement therapy using medications like carbidopa and levodopa. The medications like COMT inhibitors, dopamine agonists, and MAO-B inhibitors are widely used to treat PD. The surgical procedures, like lesioning and deep-brain stimulation, are used to control motor symptoms.

The common symptoms of parkinson’s include stiffness in muscles, postural instability, tremor, bradykinesia, autonomic problems, sleep issues, sensory changes, and pain. The disease creates a dopamine deficiency and is a neurodegenerative disorder. The supportive therapies like occupational therapy, healthy diet, physical therapy, aerobic exercise, and speech therapy help to manage PD conditions.

Parkinson’s Disease Therapeutics Market Highlights:

• In terms of revenue, the worldwide parkinson’s disease therapeutics market is projected to reach over USD 7.49 billion in 2024.
• It is projected to reach USD 12.35 billion by 2033.
• The market is expected to expand at a strong CAGR of 7.39% from 2025 to 2034.
• North America accounted for the highest market share of 34.60% in 2024.
• Europe is growing at the fastest CAGR from 2025 to 2034.
• By drug class, the levodopa/carbidopa segment held the major market share of 50.93% in 2024.
• By drug class, the COMT inhibitors segment is expected to grow at the fastest CAGR during the forecast period.
• By route of administration, the oral segment accounted for the biggest market share of 63.18% in 2024.
• By patient, the adult segment held the largest market share of 84.89% in 2024.

Emerging Market Trends in Parkinson’s Disease Therapeutics:

1. Innovative Drug–Device Combinations
   • New medication-device hybrids are entering the market, enabling continuous delivery of treatments like apomorphine through wearable systems—offering greater convenience and symptom control.
2. Advances in Long-Acting Infusion Therapies
   • Subcutaneous and infusion-based therapies now provide 24-hour control of motor fluctuations, significantly reducing “off episodes” and improving patient quality of life.
3. Selective Dopamine Receptor Agonists
   • Drugs targeting specific dopamine receptors (e.g., D1/D5) are showing promising Phase III results, offering potentially better outcomes with fewer side effects.
4. Precision Medicine & Patient-Centric Approaches
   • Customizing treatments based on genetic profiles is gaining traction, enhancing therapeutic efficacy and minimizing adverse effects.

Case Study: Supernus Pharmaceuticals’ ONAPGO FDA Approval in 2025

In February 2025, Supernus Pharmaceuticals announced the FDA approval of ONAPGO, a subcutaneous apomorphine infusion device for adults with Parkinson’s disease. The device provides continuous 24-hour delivery of apomorphine, a dopamine agonist, designed to reduce motor fluctuations and “off episodes.”

Unlike traditional oral tablets, ONAPGO uses a small wearable pump system, offering patients a less invasive and more convenient way to stabilize symptoms throughout the day. This approval marked one of the first infusion-based apomorphine treatments available in the U.S., expanding therapeutic options for patients who do not respond well to oral medications alone.

The launch highlights a growing shift toward drug–device convergence in the Parkinson’s market, where infusion-based and wearable therapies are emerging as critical innovations. Analysts note that ONAPGO positions Supernus as a competitive player in advanced Parkinson’s care, with potential to influence prescribing patterns in the U.S. and expand access to patient-centric solutions.

 

Parkinson’s Disease Therapeutics Market Opportunity

Technological Advancements Unlock Market Opportunity

The ongoing technological advancements, like surgical innovations, remote monitoring, innovations in drug discovery & delivery, and gene therapy, help in the better management of symptoms and improve motor function. The developments like subcutaneous pump systems, focused ultrasound, and advanced deep-brain stimulation control parkinson’s symptoms.

The innovations in wearable devices, integration with mobile apps, development of telemedicine, and contactless sensors help in early diagnosis of parkinson’s disease. The focus on the utilization of AI in drug discovery and the manufacturing of nanomedicine supports the streamlining of the drugs. The growing technological advancements create an opportunity for the growth of parkinson’s disease therapeutics market.

Limitations and Challenges in the Parkinson’s Disease Therapeutics Market

Growing Side Effects Limit Expansion of the Market

Despite several benefits of parkinson’s disease therapeutics, the growing side effects restrict the market growth. The therapeutics like levodopa and other causes side effects like dizziness, nausea, and loss of appetite. Some medications cause effects like sedation, fatigue, constipation, dry mouth, and blurred vision. The long-term use of medications like Levodopa causes side effects like dyskinesia, delusions, psychosis, and hallucinations.

Some therapeutic causes issues like compulsive behaviors, including hypersexuality, gambling, and shopping. The problems like swelling, fibrosis, memory problems, and cognitive impairment are caused due to the consumption of PD therapeutics. The growing side effects hamper the growth of the parkinson’s disease therapeutics market.

Scope of Market